NCT07190235Not yet recruiting
The Effect of rTMS Over the SMA on Gait Performance in Parkinson's Disease
The Effect of Repetitive Transcranial Magnetic Stimulation Over the Supplementary Motor Area on Gait Performance in Parkinson's Disease: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
This study aims to investigate the effects of high-frequency and low-frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) on gait performance, especially gait initiation, in individuals with Parkinson's disease (PD). Furthermore, the investigators will explore the impact of rTMS over the SMA on walking speed, functional mobility, and limits of stability in PD. It is hypothesized that rTMS over the SMA will improve gait performance in PD.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 81 (estimated)
- First submitted
- 16 Sept 2025
- Start date
- 6 Jan 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- The Hong Kong Polytechnic University
- Diseases
- Parkinson disease
- NCT number
- NCT07190235
What you commit to
- Study type: Interventional
- Planned participants: 81
- From 6 Jan 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with unstable medical conditions,
- other neurological conditions including stroke,
Other
- unable to provide informed consent,
- contraindications for TMS,
- experienced deep brain stimulation treatment,
- no recordable motor evoked potentials (MEPs) with TMS.
Who the study is looking for
- diagnosed with PD according to thecriteria set by Movement Disorder Committee,
- with Hoehn and Yahr stages II-III, which are recognized as representing mild to moderate disease severity,
- have self-reported difficulty in gait initiation, assessed by item 5 of the freezing of gait questionnaire (FOGQ),
- have used a dopaminergic medication dose in the last month,
- a minimum score of 23 of 30 points on the Montreal Cognitive Assessment (MoCA).
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Hong Kong Polytechnic University Coordinator of this site? Confirm its status | Kowloon | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.